Press Releases 2009

  • 11/17/2009
    IntelGenx Achieves Positive Bioequivalence Results With Novel Anti-Migraine Film
  • 11/10/2009
    IntelGenx Reports Results For the Third Quarter and Nine Months Ended September 30, 2009
  • 10/06/2009
    IntelGenx Determines Exercise Price of Stock Options to IR Firm
  • 10/01/2009
    IntelGenx Strengthens Investor Relations Activities
  • 09/04/2009
    IntelGenx Technologies Corp. Completes Additional Private Placement
  • 08/31/2009
    IntelGenx Technologies Corp. Announces Shareholder Call
  • 08/21/2009
    IntelGenx Corp. Comments on CPI-300 Patent Infringement Complaint
  • 08/14/2009
    IntelGenx Reports Results for the Second Quarter and Six Months Ended June 30, 2009
  • 07/29/2009
    IntelGenx Technologies Corp. Files Preliminary Short Form Prospectus; IntelGenx Completes Additional Private Placement
  • 07/14/2009
    IntelGenx Technologies Corp. Announces Closing of Private Placement
  • 06/23/2009
    IntelGenx Corp. Announces FDA Acceptance for Filing of NDA for CPI-300 Antidepressant
  • 05/19/2009
    IntelGenx Corp. and Circ Pharma to Commence Phase 1 Proof-of-Concept Study of CRES Pravastatin, a Novel Low Dose Formulation Containing Pravastatin for the Treatment of Hyperlipidemia
  • 05/13/2009
    IntelGenx Reports Results for the First Quarter of 2009
  • 04/20/2009
    Positive Bioequivalence Results for IntelGenx Developed Product
  • 04/15/2009
    IntelGenx Announces Appointment of New Director
  • 04/14/2009
    Cannasat and IntelGenx Announce Positive Phase 1(b) Results Improved buccal tablet outperforms oral dronabinol
  • 04/07/2009
    IntelGenx Corp. and Cary Pharmaceuticals file NDA for CPI-300 antidepressant
  • 03/25/2009
    IntelGenx Technologies Corp. Announces 2008 Annual Financial Results
  • 01/28/2009
    Cannasat Therapeutics and IntelGenx Corp. Reach Key Milestone
  • 01/19/2009
    IntelGenx Corp. and Circ Pharma Ltd announced today a partnership to develop and commercialise a novel drug for the treatment of hyperlipidemia.